This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Insulin resistance (IR) is known to be associated with increased risk for cardiovascular disease (CVD) and Type 2 diabetes. Atypical antipsychotic medications are thought to make individuals more IR. The proposed study is a pre/post, single-site, unblinded pilot-study of 20-30 patients changing from one atypical antipsychotic to aripiprazole. The purpose of this study is to evaluate the mechanism of action associated with excessive weight gain secondary to atypical antipsychotics. The design focuses on pre- and post-test evaluation of glucose metabolism and IR in conjunction with use of the second-generation drugs Clozapine and Olanzapine, versus a so-called third generation agent, Aripiprazole. Efficacy will also be examined following the switch to the third generation agent.
Showing the most recent 10 out of 589 publications